Tidligere arrangementer

How can AI help innovators spend less time on paperwork and more on moving their ideas forward? 

Hva kan nordmenn dø av i 2040, og hva kan forskningen gjøre for at vi overlever?

NCMBM is organising a new seminar series in the Life Science Building this autumn. The series will give researchers and colleagues working in and around the building an opportunity to get to know each other’s research and the different research environments.

Speakers: Jukka Corander and Anthony Mathelier

Fiskedød, algeinvasjon, økte nitrogenutslipp, fiskeforbud og stadig flere restriksjoner preger Oslofjorden. Hva skal til for å gi fjorden livet tilbake?

The Science Studies Colloquium Series (Forum for vitenskapsteori) organizes a seminar presenting the new evaluation report for UiO:Life Science 

Join and learn how early regulatory planning can support the development of your idea into a compliant medical device.

A clear understanding of your competitive advantages and the needs of your end users is essential for turning a promising idea into a compelling market offering. Insight into customer priorities and unmet needs not only strengthens your strategic positioning but also enhances your credibility when engaging potential partners and investors.

How to secure funding? 

Welcome to a life sciences IP workshop led by two experienced life sciences patent attorneys from Abel & Imray LLP.

Bringing together academic and industry in a one-day symposium featuring key notes, project presentations, flash talks, industry presentations, start-up session, round table discussion and poster session.

Få et overblikk over de viktigste bioteknologinyhetene – fra laboratorieskapte kjønnsceller og nye metoder mot hjernesykdommer, til genetiske grep i landbruket og politiets bruk av avanserte DNA-analyser.

Join us for a seminar highlighting the breadth of real-world evidence (RWE) research on Pharmaceuticals at the University of Oslo—spanning drug utilization, effectiveness, and safety studies of pharmaceuticals and vaccines. Using Norway’s world-class health registries, clinical trial data, and advanced analytical methods, UiO researchers are generating cutting-edge evidence to support clinical practice, public health, and regulatory decision-making.

The Johnson & Johnson external innovation team will present J&J’s external collaboration model and meet innovative emerging companies and start-ups, as well as researchers, academics and organisations based in Norway and the broader Nordic region who are active in the Pharmaceutical and MedTech sectors. 

A half-day demonstration and hands-on workshop on organoids and organ-on-chip platforms where start-ups, PIs, PDs and PhDs can get hands-on practical training.

In this workshop you will learn to look at and listen to your image data in the real-time Jupyter Notebook environment, using Pixasonics.

Welcome to a public talk and guest lecture with professor Chair of the Department of Biostatistics at the Harvard T.H. Chan School of Public Health, Professor in the Channing Division of Network Medicine of Brigham and Women’s Hospital, and Professor at Dana-Farber Cancer Institute.

Welcome to guest lectures by Rino Rappuoli and Emanuele Andreano. Prof Rappaouli is one of the world leading experts on vaccines and the Scientific Director of the Biotecnopolo di Siena Foundation, Italy. 

Velkommen til Livsvitenskapskonferansen – Norway Life Science 2026!

Turning a promising discovery into an approved medicine is as much about strategy and compliance as it is about science.

The NorMIC workshop series aims to teach biological researchers the principles of biological microscopy and image processing.

Welcome to a seminar for employees who will work in the Life Science Building.

Velkommen til seminar for deg som skal ha Livsvitenskapsbygget som arbeidssted.

How do we protect sensitive data, ensure ethical AI, and safeguard critical assets?

These challenges can define the difference between success and vulnerability. Data breaches can undermine trust, AI decisions can raise ethical concerns, and uncontrolled assets can disrupt progress.